Nemaura, the British company behind the BEAT technology platform for biomarker monitoring, has announced promising financial results. In addition, the firm has also recently won two innovation awards for its work with non-invasive biosensors. The results bode well for MySugarWatch, which aims to give type 2 diabetics an affordable needle-free continuous glucose monitor.
https://www.notebookcheck.net/MySugarWatch-needle-free-continuous-glucose-monitor-for-type-2-diabetes-on-the-cards-as-award-winning-Nemaura-posts-encouraging-financials.605046.0.html